A single-arm clinical trial found that FMT (fecal microbiota transplantation) and anti-PD-1 therapy altered the PD-1 response in selected patients with advanced melanoma resistance by altering the gut microbiota and reprogramming the tumor microenvironment (67). This evidence concerns the gene PDCD1 and melanoma.